1. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. (March 2018) Authors: Gerber, David E.; Socinski, Mark A.; Neal, Joel W.; Wakelee, Heather A.; Shirai, Keisuke; Sequist, Lecia V.; Rosovsky, Rachel P.; Lilenbaum, Rogerio C.; Bastos, Bruno R.; Huang, Chao; Johnson, Melissa L.; Hesketh, Paul J.; Subramaniam, Deepa S.; Dietrich, Martin F.; Chai, Feng; Wang, Yunxia; Kaza... Journal: Lung cancer Issue: Volume 117(2018) Page Start: 44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗